Your shopping cart is currently empty

Resiniferatoxin ((+)-Resiniferatoxin) is a highly potent synthetic TRPV1 agonist that inhibits the production of Th1 cytokines and has anti-inflammatory activity, reducing serum levels of IL-12, INF-γ, IL-1β, TNF-α, NO, and PGE.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $456 | - | In Stock | |
| 5 mg | $1,130 | In Stock | In Stock | |
| 10 mg | $1,530 | 6-8 weeks | 6-8 weeks | |
| 1 mL x 10 mM (in DMSO) | $1,380 | 6-8 weeks | 6-8 weeks |
| Description | Resiniferatoxin ((+)-Resiniferatoxin) is a highly potent synthetic TRPV1 agonist that inhibits the production of Th1 cytokines and has anti-inflammatory activity, reducing serum levels of IL-12, INF-γ, IL-1β, TNF-α, NO, and PGE. |
| In vitro | METHODS: RAW264.7 cells were treated with LPS (100 ng/ml) and IFN-γ (3 ng ml−1) and then treated with Resiniferatoxin ((+)-Resiniferatoxin) (0.01, 0.1, 1, 10.24 h). The culture medium was collected for NO determination, and the cell lysates were subjected to SDS-PAGE to measure and quantify iNOS or COX-2 immunoreactivity. RESULTS At a concentration of 10 μM, Resiniferatoxin ((+)-Resiniferatoxin) inhibited LPS-induced NO production by 67±10% and 52±6%, respectively, and failed to affect LPS-induced COX-2 and PGE2 responses. [3] |
| In vivo | METHODS: Resiniferatoxin ((+)-Resiniferatoxin) (2 μg/10 μl) was injected intrathecally into the T2/T3 space of mice. Cardiac sympathetic nerve activity (CSNA) and cardiac electrophysiology were assessed two weeks later. RESULTS Intrathecal injection of Resiniferatoxin ((+)-Resiniferatoxin) significantly and selectively eliminated the expression of dorsal horn afferent markers (TRPV1 and calcitonin gene-related peptide) and reduced overactive CSNA. Electrophysiological studies have shown that intrathecal administration of Resiniferatoxin ((+)-Resiniferatoxin) can significantly reverse the prolongation of action potential duration (APD) and APD alternating hormones and reduce the inducibility of ventricular arrhythmias. [4] |
| Synonyms | RTX, [3H]resiniferatoxin |
| Molecular Weight | 628.71 |
| Formula | C37H40O9 |
| Cas No. | 57444-62-9 |
| Smiles | C[C@H]1[C@]23[C@]([C@@]4([C@](C(C)=C)(C1)O[C@](CC5=CC=CC=C5)(O2)O4)[H])(C=C(COC(CC6=CC(OC)=C(O)C=C6)=O)C[C@@]7(O)[C@]3(C=C(C)C7=O)[H])[H] |
| Relative Density. | 1.35g/cm3 |
| Storage | store at low temperature,keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 32 mg/mL (50.9 mM) | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (1.59 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.